MedTech Perspectives | Monday, September 20, 2021
Occuity plans to continue hiring top minds in their disciplines, creating jobs in Reading and the Thames Valley, having grown from a workforce of 10 in December 2020 to more than 35 today.
FREMONT, California: Occuity, a medical technology start-up based in the Thames Valley, hit its Â£ 1.8million fundraising goal just 24 hours after launching on Seedrs, the leading crowdfunding site. The company now plans to “over-fund” as long as the lathe is still available, allowing it to accelerate the development of its unique optical devices.
CEO and Co-Founder Dr Dan Daly comments: âWe are delighted with the level of interest we have received during this roundtable and are delighted that we are overfunding now. To date, we have raised more than 2 million pounds, which will allow us to accelerate the development of our new optical screening and monitoring devices that aim to detect the first signs of chronic health problems by scanning the eye. human. ”
Occuity, founded in 2019, invented and patented a non-contact optical technique that allows it to take exact measurements from the eye. The company’s mission is to use the eye as a window to the health of the body and to use its wearable, non-invasive, contactless technology to bring a variety of new medical devices to market; including eye exams, prediabetes screening, diabetes management, and long-term early detection of Alzheimer’s disease.
âDiabetes is a very personal problem and of course once you have it it is likely to be with you for the rest of your life. As our long-term products will be personal use meters for people with diabetes, we wanted to give our community of 8,000 people with diabetes the opportunity to become full shareholders of our company and join us. on this journey to try to improve their lives, âDr Daly said:
Occuity intends to use the funds raised in this round to expand its team. The company plans to continue hiring the top minds in their disciplines, creating jobs in Reading and the Thames Valley, having grown from a workforce of 10 in December 2020 to more than 35 today. By 2023, the company plans to employ 100 people.
The following items are included in Occuity’s new medical device deployment plan:
The PM1 Pachymeter, Occuity’s first gadget, is aimed at the optometry industry and measures corneal thickness with micrometric precision. Clinical trials will start soon and its use is expected to be approved in the EU in early 2022.
In 2024, the company hopes to deliver a prediabetes screening gadget in pharmacies and opticians, enabling mass testing for early indicators of type 2 diabetes.
He plans to launch a non-invasive personal optical glucometer in 2025, allowing people with diabetes to check their blood sugar levels without having to draw blood.
Occuity assures that its research and development will help bring to market routine screening equipment capable of detecting the first indicators of Alzheimer’s disease by detecting biomarkers deposited in the eye.